Schreiner, Philipp http://orcid.org/0000-0003-1610-1925
Greuter, Thomas
Tatu, Aurora
Keller, Dagmar I.
Straumann, Alex
Biedermann, Luc
Funding for this research was provided by:
Universität Zürich
Article History
Received: 19 September 2020
Accepted: 6 August 2021
First Online: 16 August 2021
Declarations
:
: PS received consulting fees from Pfizer, Takeda and Janssen-Cilag and travel support from Falk, UCB and Pfizer. TG has consulting contracts with Sanofi-Regeneron and Falk Pharma GmbH, received travel grants from Falk Pharma GmbH and Vifor, and an unrestricted research grant from Novartis. AT has no conflict of interest. DIK has no conflict of interest. AS reports receiving consulting fees from Allakos, AstraZeneca, EsoCap, Dr. Falk Pharma, Gossamer, GSK, Receptos-Celgene and Regeneron-Sanofi. LB received consulting fees and/or speaker fees and/or research grants from Dr. Falk Pharma, GmbH, Germany, Vifor AG, Switzerland, Esocap AG, Switzerland, Sanofi-Aventis AG, Switzerland and Calypso Biotech SA.